{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T07:22:59Z","timestamp":1777620179196,"version":"3.51.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","award":["POIG.01.01.02-00-069\/09"],"award-info":[{"award-number":["POIG.01.01.02-00-069\/09"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Reports"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.pharep.2015.03.008","type":"journal-article","created":{"date-parts":[[2015,4,6]],"date-time":"2015-04-06T06:58:43Z","timestamp":1428303523000},"page":"1041-1047","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Anti-thrombotic effects of nebivolol and carvedilol: Involvement of \u03b22 receptors and COX-2\/PGI2 pathways"],"prefix":"10.1007","volume":"67","author":[{"given":"Valery I.","family":"Kozlovski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalena","family":"Lomnicka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalena","family":"Bartus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalena","family":"Sternak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Chlopicki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"10.1016\/j.pharep.2015.03.008_bib0205","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/S0022-3565(25)10549-1","article-title":"Nebivolol vasodilates human forearm vasculature: evidence for an l-arginine\/NO-dependent mechanism","volume":"274","author":"Cockcroft","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharep.2015.03.008_bib0210","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/00005344-200009000-00006","article-title":"Nebivolol induces NO-mediated relaxations of rat small mesenteric but not of large elastic arteries","volume":"36","author":"Altwegg","year":"2000","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharep.2015.03.008_bib0215","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/S0022-3565(24)35341-8","article-title":"Inositol phosphate metabolism and nitric-oxide synthase activity in endothelial cells are involved in the vasorelaxant activity of nebivolol","volume":"292","author":"Parenti","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharep.2015.03.008_bib0220","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/0014-2999(88)90151-3","article-title":"Cardiovascular effects of dl-nebivolol and its enantiomers \u2013 a comparison with those of atenolol","volume":"156","author":"Van de Water","year":"1988","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharep.2015.03.008_bib0225","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1161\/01.CIR.102.6.677","article-title":"Nebivolol: a third-generation beta-blocker that augments vascular nitric oxide release: endothelial beta(2)-adrenergic receptor-mediated nitric oxide production","volume":"102","author":"Broeders","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.pharep.2015.03.008_bib0230","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ejphar.2004.11.043","article-title":"The cellular mechanisms involved in the vasodilator effect of nebivolol on the renal artery","volume":"508","author":"Georgescu","year":"2005","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharep.2015.03.008_bib0235","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1159\/000110011","article-title":"Nebivolol induces a hyperpolarizing effect on smooth muscle cells in the mouse renal artery by activation of beta-2-adrenoceptors","volume":"81","author":"Georgescu","year":"2008","journal-title":"Pharmacology"},{"key":"10.1016\/j.pharep.2015.03.008_bib0240","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.phrs.2006.12.008","article-title":"Effect of dl-nebivolol, its enantiomers and metabolites on the intracellular production of superoxide and nitric oxide in human endothelial cells","volume":"55","author":"Evangelista","year":"2007","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.pharep.2015.03.008_bib0245","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/j.1476-5381.2009.00074.x","article-title":"Investigation of the different adrenoceptor targets of nebivolol enantiomers in rat thoracic aorta","volume":"156","author":"Tran Quang","year":"2009","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharep.2015.03.008_bib0250","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/00005344-200308000-00012","article-title":"Involvement of the beta3 adrenoceptor in nebivolol-induced vasorelaxation in the rat aorta","volume":"42","author":"De Groot","year":"2003","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharep.2015.03.008_bib0255","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1161\/CIRCULATIONAHA.104.532960","article-title":"Endothelial beta3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation beta-blocker nebivolol","volume":"112","author":"Dessy","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.pharep.2015.03.008_bib0260","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1097\/00005344-199106000-00016","article-title":"Nebivolol induces endothelium-dependent relaxations of canine coronary arteries","volume":"17","author":"Gao","year":"1991","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharep.2015.03.008_bib0265","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/00005344-200108000-00004","article-title":"Nebivolol induces calcium-independent signaling in endothelial cells by a possible beta-adrenergic pathway","volume":"38","author":"Gosgnach","year":"2001","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharep.2015.03.008_bib0270","doi-asserted-by":"crossref","first-page":"F775","DOI":"10.1152\/ajprenal.00233.2012","article-title":"Nebivolol-induced vasodilation of renal afferent arterioles involves \u03b23-adrenergic receptor and nitric oxide synthase activation","volume":"303","author":"Feng","year":"2012","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.pharep.2015.03.008_bib0275","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1161\/01.HYP.33.1.467","article-title":"Effects of vasodilatory beta-adrenoceptor antagonists on endothelium-derived nitric oxide release in rat kidney","volume":"33","author":"Kakoki","year":"1999","journal-title":"Hypertension"},{"key":"10.1016\/j.pharep.2015.03.008_bib0280","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1097\/00005344-200405000-00005","article-title":"Estrogen receptor-mediated vascular responsiveness to nebivolol: a novel endothelium-related mechanism of therapeutic vasorelaxation","volume":"43","author":"Garb\u00e1n","year":"2004","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharep.2015.03.008_bib0285","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1097\/HJH.0b013e32831fb389","article-title":"Nebivolol decreases endothelial cell stiffness via the estrogen receptor beta: a nano-imaging study","volume":"27","author":"Hillebrand","year":"2009","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharep.2015.03.008_bib0290","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1111\/j.1476-5381.2009.00610.x","article-title":"The selective beta1-adrenoceptor antagonist nebivolol is a potential oestrogen receptor agonist with neuroprotective abilities","volume":"159","author":"Manthey","year":"2010","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharep.2015.03.008_bib0295","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1161\/01.CIR.0000066912.58385.DE","article-title":"Third-generation beta-blockers stimulate nitric oxide release from endothelial cells through ATP efflux: a novel mechanism for antihypertensive action","volume":"107","author":"Kalinowski","year":"2003","journal-title":"Circulation"},{"issue":"Suppl.","key":"10.1016\/j.pharep.2015.03.008_bib0300","first-page":"103","article-title":"Nebivovol and carvedilol induce NO-dependent coronary vasodilatation that is unlikely to be mediated by extracellular ATP in the isolated guinea pig heart","volume":"58","author":"Kozlovski","year":"2006","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.pharep.2015.03.008_bib0305","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.3892\/mmr.2013.1329","article-title":"The effects of carvedilol on cardiac structural remodeling: the role of endogenous nitric oxide in the activity of carvedilol","volume":"7","author":"Chen","year":"2013","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.pharep.2015.03.008_bib0310","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.amjhyper.2007.01.019","article-title":"Effects of carvedilol versus metoprolol on endothelial function and oxidative stress in patients with type 2 diabetes mellitus","volume":"20","author":"Bank","year":"2007","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.pharep.2015.03.008_bib0315","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1136\/hrt.2006.087999","article-title":"Carvedilol improves endothelium-dependent vasodilation in patients with dilated cardiomyopathy","volume":"93","author":"Nishioka","year":"2007","journal-title":"Heart"},{"key":"10.1016\/j.pharep.2015.03.008_bib0320","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1038\/ajh.2008.260","article-title":"Nebivolol treatment reduces serum levels of asymmetric dimethylarginine and improves endothelial dysfunction in essential hypertensive patients","volume":"21","author":"Pasini","year":"2008","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.pharep.2015.03.008_bib0325","first-page":"45","article-title":"Effects of nebivolol versus bisoprolol on endothelial function in hypertensive patients","volume":"14","author":"Simova","year":"2009","journal-title":"Exp Clin Cardiol"},{"key":"10.1016\/j.pharep.2015.03.008_bib0330","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s00380-009-1170-1","article-title":"Effects of nebivolol therapy on endothelial functions in cardiac syndrome X","volume":"25","author":"Kayaalti","year":"2010","journal-title":"Heart Vessels"},{"key":"10.1016\/j.pharep.2015.03.008_bib0335","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1742-7843.2012.00911.x","article-title":"Effect of carvedilol and nebivolol on oxidative stress-related parameters and endothelial function in patients with essential hypertension","volume":"111","author":"Zepeda","year":"2012","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.pharep.2015.03.008_bib0340","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1097\/00005344-200112000-00014","article-title":"Effects of nebivolol on human platelet aggregation","volume":"38","author":"Falciani","year":"2001","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharep.2015.03.008_bib0345","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ijcard.2006.03.046","article-title":"Effects of nebivolol on platelet activation in hypertensive patients: a comparative study with metoprolol","volume":"116","author":"Celik","year":"2007","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.pharep.2015.03.008_bib0350","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1080\/0953710021000057848","article-title":"Antiplatelet activity of carvedilol in comparison to propranolol","volume":"13","author":"Petr\u00edkov\u00e1","year":"2002","journal-title":"Platelets"},{"key":"10.1016\/j.pharep.2015.03.008_bib0355","first-page":"1","article-title":"Significance of endothelial prostacyclin and nitric oxide in peripheral and pulmonary circulation","volume":"7","author":"Gryglewski","year":"2001","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.pharep.2015.03.008_bib0360","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/sj.bjp.0707383","article-title":"1-Methylnicotinamide (MNA), a primary metabolite of nicotinamide, exerts anti-thrombotic activity mediated by a cyclooxygenase-2\/prostacyclin pathway","volume":"152","author":"Chlopicki","year":"2007","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharep.2015.03.008_bib0365","first-page":"605","article-title":"Reversal of the postischaemic suppression of coronary function in perfused guinea pig heart by ischaemic preconditioning","volume":"50","author":"Chlopicki","year":"1999","journal-title":"J Physiol Pharmacol"},{"key":"10.1016\/j.pharep.2015.03.008_bib0370","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/0021-9673(95)01114-5","article-title":"Location of the hydroxyl functions in hydroxylated metabolites of nebivolol in different animal species and human subjects as determined by on-line high-performance liquid chromatography-diode-array detection","volume":"729","author":"Hendrickx","year":"1996","journal-title":"J Chromatogr A"},{"key":"10.1016\/j.pharep.2015.03.008_bib0375","first-page":"958","article-title":"Metabolism of carvedilol in dogs, rats, and mice","volume":"26","author":"Schaefer","year":"1998","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.pharep.2015.03.008_bib0380","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1749-6632.2001.tb03945.x","article-title":"Comparison of endothelial pleiotropic actions of angiotensin converting enzyme inhibitors and statins","volume":"947","author":"Gryglewski","year":"2001","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.pharep.2015.03.008_bib0385","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1097\/00005344-200305000-00006","article-title":"Effects of two beta3-agonists, CGP 12177A and BRL 37344, on coronary flow and contractility in isolated guinea pig heart","volume":"41","author":"Kozlovski","year":"2003","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharep.2015.03.008_bib0390","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1111\/j.1476-5381.2010.01148.x","article-title":"EDHF: spreading the influence of the endothelium","volume":"164","author":"Garland","year":"2011","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharep.2015.03.008_bib0395","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/j.1440-1681.2006.04386.x","article-title":"Vasorelaxing effects of propranolol in rat aorta and mesenteric artery: a role for nitric oxide and calcium entry blockade","volume":"33","author":"Priviero","year":"2006","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.pharep.2015.03.008_bib0400","doi-asserted-by":"crossref","first-page":"909","DOI":"10.2147\/VHRM.S3020","article-title":"Effects of the vasodilating beta-blocker nebivolol on smoking-induced endothelial dysfunction in young healthy volunteers","volume":"4","author":"Schmidt","year":"2008","journal-title":"Vasc Health Risk Manag"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S173411401500047X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S173411401500047X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T20:35:59Z","timestamp":1752611759000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1016\/j.pharep.2015.03.008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S173411401500047X"],"URL":"https:\/\/doi.org\/10.1016\/j.pharep.2015.03.008","relation":{},"ISSN":["1734-1140"],"issn-type":[{"value":"1734-1140","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-thrombotic effects of nebivolol and carvedilol: Involvement of \u03b22 receptors and COX-2\/PGI2 pathways","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharep.2015.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier Urban & Partner Sp. z o.o. All rights reserved.","name":"copyright","label":"Copyright"}]}}